Cargando…

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting

BACKGROUND: Direct-acting antivirals (DAAs) offer high cure rates in people who inject drugs (PWID) with hepatitis C virus (HCV) infection. There are concerns regarding lower response rates among PWID in real life. We evaluated the outcome of DAA therapy in PWID in a real-world setting and the facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koustenis, Kanellos Rafail, Anagnostou, Olga, Kranidioti, Hariklia, Vasileiadi, Sofia, Antonakaki, Pinelopi, Koutli, Evangelia, Pantsas, Paris, Deutsch, Melanie, Manolakopoulos, Spilios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049240/ https://www.ncbi.nlm.nih.gov/pubmed/32127741 http://dx.doi.org/10.20524/aog.2020.0449

Ejemplares similares

Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography
por: Papadopoulos, Nikolaos, et al.
Publicado: (2019)

Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis
por: Kranidioti, Hariklia, et al.
Publicado: (2018)

Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
por: Kranidioti, Hariklia, et al.
Publicado: (2015)

Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein
por: Deutsch, Melanie, et al.
Publicado: (2018)

Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues
por: Papadopoulos, Nikolaos, et al.
Publicado: (2018)

Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C
por: Papageorgiou, Maria-Vasiliki, et al.
Publicado: (2011)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease may develop in individuals with normal body mass index
por: Margariti, Ekaterini, et al.
Publicado: (2012)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

The Arising Role of Extracellular Vesicles in Cholangiocarcinoma: A Rundown of the Current Knowledge Regarding Diagnostic and Therapeutic Approaches
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2023)

COVID-19 and liver injury: where do we stand?
por: Papadopoulos, Nikolaos, et al.
Publicado: (2020)

Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience
por: Manolakopoulos, Spilios, et al.
Publicado: (2015)

Endotoxin Translocation and Gut Barrier Dysfunction Are Related to Variceal Bleeding in Patients With Liver Cirrhosis
por: Triantos, Christos, et al.
Publicado: (2022)

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
por: Manolakopoulos, Spilios, et al.
Publicado: (2016)

Role of band ligation for secondary prophylaxis of variceal bleeding
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2018)

Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management
por: Spanoudaki, Anastasia, et al.
Publicado: (2022)

Aiming towards hepatitis C virus elimination in Greece
por: Papatheodoridis, George V., et al.
Publicado: (2019)

The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C
por: Savvoula, Savvidou, et al.
Publicado: (2012)

Epidemiology of hepatitis C in Greece
por: Triantos, Christos, et al.
Publicado: (2016)

Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic
por: Apostolou, Theofanis, et al.
Publicado: (2020)

Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice
por: Papatheodoridi, Μargarita, et al.
Publicado: (2017)

Serum zonulin levels in patients with liver cirrhosis: Prognostic implications
por: Voulgaris, Theodoros A, et al.
Publicado: (2021)

Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019
por: Tziolos, Nikolaos, et al.
Publicado: (2021)

Development of tools for automatic generation of PLC code
por: Koutli, Maria
Publicado: (2014)

Pretreatment serum interleukin-12 levels in predicting sustained virological response among hepatitis C patients following Pegylated Interferon-α2β plus Ribavirin treatment
por: Perperas, Antony, et al.
Publicado: (2013)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Rectal Cancer: Multimodal Treatment Approach
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2012)

Endoscopic treatment for high-risk bleeding peptic ulcers: a comparison of epinephrine alone with epinephrine plus ethanolamine
por: Konstantinidis, Anastasios, et al.
Publicado: (2011)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus
por: Mawatari, Seiichi, et al.
Publicado: (2022)

An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study
por: Manolakopoulos, Spilios, et al.
Publicado: (2007)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Influenza Antiviral Subversion: Now the Host Is in on the Act
por: Yepsen, Erin N., et al.
Publicado: (2021)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
por: Lee, Hyun Woong, et al.
Publicado: (2017)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
por: Hsu, Jui-Ting, et al.
Publicado: (2022)

Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago
por: Tatara, Eric, et al.
Publicado: (2022)

Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy
por: Yazdani, Kiana, et al.
Publicado: (2022)

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
por: Sarıgül Yıldırım, Figen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5pligpgi09grai7ijmul7ts04q